lillydirect tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly Adds Highest Doses

MAESTRO-NASH retrospectively assessed participants for a history of significant alcohol consumption, specifically looking for patterns lasting more than three consecutive months within the year preceding the screening process

If you have Medicare Part D coming online in July, hold for the $50 tier

Tirzepatide appears to have a peculiar impact on atherogenic dyslipidemia compared to GLP-1R monoagonists, with a preferential benefit on triglyceride levels [78, 79]

Prices vary by medication and pharmacy location

View the full report here: What Are the Key Growth Drivers Fueling the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Expansion